Nuron Biotech develops novel biologics and vaccines targeting neurodegenerative and infectious diseases. Its vaccine brands include Meningitec™ and HibTITER®, and its lead therapeutic candidate is NU100 (interferon beta-1b), currently in a Phase 3 trial for multiple sclerosis. The company recently acquired Meningitec from Pfizer and plans to commercialize and expand that product. Nuron will use proceeds from the financing to support Meningitec commercialization and to advance clinical development of its pipeline, including NU100. The firm emphasizes unmet medical needs and is led by a team of industry veterans committed to global patient access. Financially, Nuron closed an $80 million financing that mixes near-term commercial support with funding for pipeline advancement.

Total raised

$80M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Dec 2012